Daniel Petree
Director/Board Member chez SUTRO BIOPHARMA, INC.
Fortune : 126 882 $ au 31/03/2024
Profil
Daniel H.
Petree is the founder of P2 Partners LLC (2000), Four Oaks Partners LLC (2012), and Four Oaks Partners Consulting LLC (2012).
He is currently an Independent Director at Sutro Biopharma, Inc. (since 2009) and Director & Head-Corporate Development at Lipidio Pharmaceuticals, Inc. (current).
He previously held positions such as Chairman at Lpath, Inc. (2008-2016), President & Chief Operating Officer at Axys Pharmaceuticals, Inc. (1993-1999), and Vice President-Health Care Group at Montgomery Securities, Inc. He also has a background in law, having received his graduate degree from The University of Michigan Law School in 1981.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SUTRO BIOPHARMA, INC.
0,04% | 27/06/2023 | 22 457 ( 0,04% ) | 126 882 $ | 31/03/2024 |
Postes actifs de Daniel Petree
| Sociétés | Poste | Début |
|---|---|---|
| SUTRO BIOPHARMA, INC. | Director/Board Member | 01/08/2009 |
Lipidio Pharmaceuticals, Inc.
 Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | Director/Board Member | - |
Anciens postes connus de Daniel Petree
| Sociétés | Poste | Fin |
|---|---|---|
| Four Oaks Partners Consulting LLC | Founder | 01/01/2021 |
| Four Oaks Partners LLC | Chief Executive Officer | 01/01/2021 |
Lpath, Inc.
 Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Chairman | 01/01/2016 |
| BIOCEPT, INC. | Director/Board Member | 01/01/2013 |
P2 Partners LLC
 P2 Partners LLC Financial ConglomeratesFinance P2 Partners LLC operates as a strategic financial advisory services firm. The company was founded by Daniel H. Petree and is headquartered in Sacramento, CA. | Founder | 01/01/2012 |
Formation de Daniel Petree
| Stanford University | Undergraduate Degree |
| The University of Michigan Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOCEPT, INC. | Health Technology |
| SUTRO BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
Cypress Bioscience, Inc.
 Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | Health Technology |
Axys Pharmaceuticals, Inc.
 Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
| Montgomery Securities, Inc. | Finance |
| TSI Corp | Commercial Services |
| Arris Pharmaceuticals Corp. | |
Lpath, Inc.
Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Health Technology |
P2 Partners LLC
P2 Partners LLC Financial ConglomeratesFinance P2 Partners LLC operates as a strategic financial advisory services firm. The company was founded by Daniel H. Petree and is headquartered in Sacramento, CA. | Finance |
Koronis Pharmaceuticals, Inc.
 Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | Health Technology |
Heller Ehrman White & McAuliffe LLP
 Heller Ehrman White & McAuliffe LLP Miscellaneous Commercial ServicesCommercial Services Heller Ehrman White & McAuliffe LLP is a private company based in San Francisco, CA. | Commercial Services |
NKT Therapeutics, Inc.
 NKT Therapeutics, Inc. BiotechnologyHealth Technology NKT Therapeutics, Inc. operates as a biotechnology company. It focuses on developing therapeutics based on unique immune cells called natural killer NKT cells. The company was founded by Alem Truneh, S. Brian Wilson, Mark Exley, Steve K. Balk, and Mark A. Tepper on November 20, 2008 and is headquartered in Waltham, MA. | Health Technology |
| Four Oaks Partners LLC | |
| Four Oaks Partners Consulting LLC | |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | Health Technology |
